Search | DIAL.pr - BOREAL

Accès à distance ? S'identifier sur le proxy UCLouvain

Displaying 1 result.

- Speech
Rituximab given after high dose therapy and autologous stem cell transplantation induces durable clearance of minimal residual disease in about half of the patients with follicular non Hodgkin's lymphoma: 36 months results of a multicenter open label phase II trial (M39012 trial).
Morschhauser, F. Recher, C. Milpied, N. Gressin, R Salles, G. Brice, P. Vey, N Haioun, C. Colombat, P Bourhis, JH Rossi, JF Berriot-Varoqueaux, N Bergougnoux, L Bosly, André[UCL] Delsol, G. Attal, M. (2004) 46th Annual Meeting of the American-Society-of-Hematology — San Diego(Ca)